Following the referral of lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer to NICE by the Department for Health and Social Care. Following on from advice received from the company, the timelines are currently to be confirmed. Therefore, we are suspending this appraisal. We will provide a further update and timelines in due course.